Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Exit

CureVac files for IPO
CureVac has filed for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.
iTeos takes $201m in flotation
Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to UCL and Ludwig Institute.
Nurix negotiates $209m IPO
Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.
4D Molecular forgoes IPO option
UC Berkeley's genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.
Freeline progresses towards $100m IPO
UCL's gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.
Berkeley Lights beams on to public markets
UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.
Relay receives $400m in initial public offering
The oncology therapy developer has gone public in an upsized offering that provided an exit to Third Rock Ventures.
Curavi completes three-way merger
UPMC's patient telemedicine service Curavi Health has completed a merger that enables its founding institution to retain an equity stake.

Other News

Century assimilates Empirica Therapeutics
University of Toronto and McMaster University-founded glioblastoma Car T-cell therapy developer Empirca Therapeutics has been acquired by Century Therapeutics.
LGC screens Native Antigen Company
University of Birmingham‘s infectious disease reagent producer Native Antigen Company has been acquired in a deal enabling Mercia Asset Management to exit.
Cambricon cashes $368m in IPO
CAS-backed AI processor provider Cambricon, valued at $2.5bn in 2018, floated on Shanghai's Star Market.
AlloVir approaches public markets
Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.
Nurix picks Nasdaq for $100m IPO filing
UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.
Inozyme ignites IPO proceedings
Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg

Login